Comparative long-term efficacy of ivermectin and moxidectin over winter in Canadian horses treated at removal from pastures for winter housing

The impact of a late fall treatment on the spring rise of fecal egg counts was evaluated in a controlled study with Canadian horses treated with 2 different dewormers immediately after removal from pasture for winter housing. The horses were stabled until the end of the trial period. Seventeen weanlings, 20 yearlings, and 15 2-year-old horses located in Ontario, which were presumed to be naturally infected with cyathostomins after pasture grazing, were randomly allocated to either a group treated with 0.4 mg/kg of moxidectin and 2.5 mg/kg of praziquantel or a group treated with 0.2 mg/kg of ivermectin and 1.5 mg/kg of praziquantel. Three weeks after treatment, all strongyle fecal egg counts were reduced to zero for both treatment groups. However, at 5 months post-treatment, mean geometric fecal egg counts were statistically higher for the yearlings and 2-year-old horses treated with ivermectin than for the yearlings and 2-year-old horses treated with moxidectin (P < 0.0001).     

Comparison of ivermectin, oxibendazole, and pyrantel pamoate in suppressing fecal egg output in horses

Thirty resident horses at a boarding stable in Alberta were used to evaluate the relative efficacies of ivermectin, oxibendazole, and pyrantel pamoate in reducing fecal egg output in adult horses under routine management conditions during spring and early summer, and to more clearly define the duration of suppression of fecal egg production following anthelmintic treatment. Horses were blocked according to pretreatment egg counts and randomly assigned to one of three treatments: pyrantel pamoate at 6.6 mg/kg body weight; oxibendazole at 10 mg/kg body weight; or ivermectin at 200 μg/kg body weight. All treatments were administered orally as a paste on day 0.Fecal samples were collected for examination by the modified Wisconsin procedure before treatment, and then at 4-11 day intervals up to day 72.

Very few if any strongyle eggs were found in the feces of any horses up to day 35. On days 42, 50 and 57, the geometric mean egg count for the ivermectin group was significantly (p<0.05) lower than that for the oxibendazole or pyrantel pamoate groups. Based on a survival curve analysis of the data, the mean number of days for recurrence of eggs in the feces was significantly longer for the ivermectin group than for the oxibendazole and pyrantel pamoate groups.

Under conditions encountered in this study, the posttreatment interval to resumption of fecal egg out-put in horses treated with ivermectin was eight to nine weeks, compared with five to six weeks for horses treated with oxibendazole or pyrantel pamoate.

     

Anti-strongyle activity of a propylene glycol-glycerol formal formulation of ivermectin in horses (mares)

Four groups of 10 horses (mares) each were treated with a 1% solution of ivermectin (200 micrograms/kg of body weight) in a propylene glycol-glycerol formal base orally, a 1% solution of ivermectin (200 micrograms/kg) in a propylene glycol-glycerol formal base via nasogastric tube, a 1.87% paste of ivermectin (200 micrograms/kg) orally, or a 22.7% paste of oxibendazole (10 mg/kg) orally. Fecal examinations were done before treatment and on posttreatment days (PTD) 14, 28, 42, 56, and 70. Strongyle egg per gram counts and sugar flotation fecal examinations were performed. Results of fecal examinations before treatment were similar in all horses. All horses treated with ivermectin had similar percentages of reductions in mean strongyle egg per gram counts after treatment; 100% on PTD 14, 28, and 56 and 93.4% to 98.7% on PTD 70. All ivermectin treatment groups had 0 horses detected as passing strongyle eggs on PTD 14 and 28, 0 to 2 on PTD 42, 3 to 5 on PTD 56, and 8 to 9 on PTD 70. Horses treated with oxibendazole had 99.9%, 99.7%, 92.9% 78.6%, and 54.5% reductions in mean strongyle egg per gram counts and 5, 7, 8, 9, and 9 horses detected as passing strongyle eggs on PTD 14, 28, 42, 56, and 70, respectively. Adverse reactions to treatment were not observed.     

Daily variability of equine fecal strongyle egg counts.

Fecal egg counts often are used for diagnosing equine strongyle infections and estimating the number of eggs shed in the feces. An individual egg count should be interpreted in view of the normal fluctuation of egg numbers in an individual horse. In this study, the daily variability of strongyle fecal egg counts from horses was investigated. The Cornell-McMaster egg-counting technique was used to estimate the eggs per gram of feces in repeated daily fecal samples from 39 horses. The variation of the daily egg counts across 4 days was greater than would be expected if a consistent number of eggs were produced and dispersed randomly in the feces. The means and variances of the daily counts from each horse had a logarithmic relationship. For practical purposes, however, the fluctuation of egg counts is low enough for the fecal egg count to be used to identify horses for treatment, to estimate pasture contamination, or to assess response to therapy.     

The persistence of benzimidazole-resistant cyathostomes on horse farms in Ontario over 10 years and the effectiveness of ivermectin and moxidectin against these resistant strains

Three clinical trials with fecal egg count reduction tests and coproculture were conducted on 2 standardbred farms in Ontario. On Farm A, the treatment groups were mebendazole and ivermectin in trial 1, and fenbendazole and moxidectin in another. On Farm B, treatment groups were mebendazole and ivermectin. All horses treated with mebendazole or fenbendazole were subsequently treated with ivermectin or moxidectin. Strongyle eggs/g feces were estimated pre- and post-treatment using the Cornell-McMaster dilution and Cornell-Wisconsin centrifugal flotation techniques. After treatment, there was no change in the arithmetic mean eggs/g feces for horses given mebendazole, and a reduction of only 49.1% for those given fenbendazole. All horses receiving ivermectin or moxidectin had their egg counts reduced to 0. Only cyathostomes were found on culture. On both farms the benzimidazole resistant strains appeared to have persisted for at least 10 years. Development of and monitoring for anthelmintic resistance are briefly discussed.     

Field efficacy of ivermectin, fenbendazole and pyrantel embonate paste anthelmintics in horses

Three anthelmintic pastes were compared in terms of their ability to suppress the output of parasite eggs in the faeces of 108 grazing horses at four sites in Britain; the horses were treated once with either ivermectin, fenbendazole or pyrantel. At each site, the horses grazed together throughout the trials which took place during the summers of 1985 and 1986. The median periods before parasite eggs reappeared in faeces were 70 days for ivermectin, 14 days for fenbendazole and 39 days for pyrantel embonate. Geometric mean faecal egg counts in the groups treated with ivermectin and pyrantel were significantly less (P less than 0.05) than in the fenbendazole group on days 21, 28, 35 and 42 after treatment. On days 49, 56, 63 and 70 the mean egg counts in the ivermectin group were significantly lower (P less than 0.05) than those in either of the other groups. The results indicated that in order to ensure minimal contamination of pastures, grazing horses treated with ivermectin paste would have required a second treatment approximately 10 weeks after the first, and to achieve similar control with fenbendazole or pyrantel embonate, a second treatment would have been required after approximately two weeks and six weeks, respectively.     

Alternative antiparasitic treatment of horses with pyrantel pamoate suspension and ivermectin oral solution compared with horses treated only with ivermectin oral solution

A practical parasite control program was evaluated in a 2-year clinical trial using pyrantel pamoate suspension (PYR) and ivermectin oral solution (IVM) in a seasonal rotation program, in comparison with continued use of IVM given at 2-month intervals. At least 15 horses in each of 2 treatment groups were distributed over 8 locations. In the alternation program, IVM was given twice (October, December) during the botfly (Gasterophilus spp.) season and again in April to treat against the lighter botfly season and to kill existing Onchocerca microfilariae prior to heavy Culicoides swarming. Pyrantel was given in February, June and August to continue suppression of strongyle infections and to treat against potentially developing Anoplocephala infections. In the program of IVM continuous use, the drug was given on the same schedule as either treatment on the alternation program.The course of strongyle infections was monitored by fecal sample analyses (EPG) at semimonthly intervals and by larval cultures of treatment pairs prepared at each treatment interval (alternation program) or at 4-month intervals (continuous IVM program). The strongyle egg count numbers were reduced to zero by the first IVM treatment, increased only slightly by the next treatment at 2 months, and repeated the reduced pattern with each treatment for 2 years. The alternation program in the first year had typical responses to each drug: IVM reducing strongyle EPG counts to zero which increased slightly at 2 months, followed by the PYR treatment, which reduced the strongyle egg counts for 4 weeks with rebound at 6 and 8 weeks. At the end of the first year and into the second, the IVM treatments of October and December established a zero or low strongyle EPG pattern which continued through the spring with PYR and IVM treatments. The second summer PYR treatments then maintained far better cyathostome control than had been reported for this drug. There may be a complementary or enhancing effect by prior treatment with ivermectin within the rotation protocol. The practical therapeutic compatibility between these 2 antiparasitics became obvious. Anoplocephala eggs were found in feces of some horses treated with IVM only, but no Anoplocephala eggs were found in post-treatment feces of horses treated on the alternation program.Strongyle larval cultures prepared as treatment pairs indicated high efficacy by ivermectin throughout the 2 years whether used alone or as a rotational drug, with improved cyathostome control by pyrantel pamoate. The combined use of EPG determinations and concurrent larval cultures in anthelmintic evaluations provide a greater spectrum of reliable results than from parasite egg counts alone.     

Efficacy studies with three formulations of cambendazole in horses.

Treatment with 3 formulations of cambendazole (paste, pellets, and suspension) was compared with thiabendazole treatment in 181 Quarter Horses (females and intact and altered males) of different ages in 2 experiments. The mean output of strongyle eggs, as measured by eggs per gram of feces (epg), was reduced by at least 95% by the 3 formulations of cambendazole compared with pretreatment epg and epg in simultaneously nonmedicated horses. Eggs of Parascaris equorum were seen in 19 of the younger horses in experiment I. Parascaris eggs were not seen in postmedication fecal samples from 14 horses treated wtih cambendazole. Of the 5 horses treated with thiabendazole, 2 had postmedication Parascaris egg counts.     

Alternative antiparasitic treatment of horses with pyrantel pamoate suspension and ivermectin oral solution compared with horses treated only with ivermectin

A practical parasite control program was evaluated in a 2-year clinical trial using pyrantel pamoate suspension (PYR) and ivermectin oral solution (IVM) in a seasonal rotation program, in comparison with continued use of IVM given at 2-month intervals. At least 15 horses in each of 2 treatment groups were distributed over 8 locations. In the alternation program, IVM was given twice (October, December) during the botfly (Gasterophilus spp.) season and again in April to treat against the lighter botfly season and to kill existing Onchocerca microfilariae prior to heavy Culicoides swarming. Pyrantel was given in February, June and August to continue suppression of strongyle infections and to treat against potentially developing Anoplocephala infections. In the program of IVM continuous use, the drug was given on the same schedule as either treatment on the alternation program.The course of strongyle infections was monitored by fecal sample analyses (EPG) at semimonthly intervals and by larval cultures of treatment pairs prepared at each treatment interval (alternation program) or at 4-month intervals (continuous IVM program). The strongyle egg count numbers were reduced to zero by the first IVM treatment, increased only slightly by the next treatment at 2 months, and repeated the reduced pattern with each treatment for 2 years. The alternation program in the first year had typical responses to each drug: IVM reducing strongyle EPG counts to zero which increased slightly at 2 months, followed by the PYR treatment, which reduced the strongyle egg counts for 4 weeks with rebound at 6 and 8 weeks. At the end of the first year and into the second, the IVM treatments of October and December established a zero or low strongyle EPG pattern which continued through the spring with PYR and IVM treatments. The second summer PYR treatments then maintained far better cyathostome control than had been reported for this drug. There may be a complementary or enhancing effect by prior treatment with ivermectin within the rotation protocol. The practical therapeutic compatibility between these 2 antiparasitics became obvious. Anoplocephala eggs were found in feces of some horses treated with IVM only, but no Anoplocephala eggs were found in post-treatment feces of horses treated on the alternation program.Strongyle larval cultures prepared as treatment pairs indicated high efficacy by ivermectin throughout the 2 years whether used alone or as a rotational drug, with improved cyathostome control by pyrantel pamoate. The combined use of EPG determinations and concurrent larval cultures in anthelmintic evaluations provide a greater spectrum of reliable results than from parasite egg counts alone.     

Strongyle egg shedding consistency in horses on farms using selective therapy in Denmark

Knowledge of horses that shed the same number of strongyle eggs over time can lead to the optimization of parasite control strategies. This study evaluated shedding of strongyle eggs in 424 horses on 10 farms when a selective anthelmintic treatment regime was used over a 3-year period. Faecal egg counts were performed twice yearly, and horses exceeding 200 eggs per gram (EPG) of faeces were treated. The results are presented as probabilities of the egg count outcome, when two previous egg counts are known. A horse with no strongyle eggs detected in the two previous faecal examinations had an 82% probability of a zero, and a 91% of being below 200 eggs per gram in the third examination. A horse with the two previous egg counts below 200 EPG had an 84% probability of being below 200 EPG the third time as well. When faecal egg counts exceeded 200 EPG on the previous two counts, the probability for a horse exceeding 200 EPG the third time was 59%. In conclusion, these data demonstrate consistent shedding from one grazing season to another in a majority of horses despite treatment of horses exceeding 200 EPG.     

Effectiveness of an ivermectin liquid formulation given by nasogastric tube against strongyles in horses

Twenty horses were treated with ivermectin either by nasogastric tube with a liquid formulation for sheep or per os with a paste formulation for horses at a dosage of 200 μg/kg of body weight. Fecal samples were collected from these horses and from ten untreated horses at the time of treatment and every 2 wk thereafter for up to 10 wk. The samples were examined for nematode eggs using the Cornell-McMaster dilution and the Cornell-Wisconsin Double Centrifugation procedures.

There were no signs of toxicosis in horses treated with ivermectin. Strongyle eggs were found in the feces of all horses before treatment. Subsequently, they were found in untreated horses, but not in treated horses at 2 wk nor in most of them for up to 8 wk after treatment. At 10 wk most of these horses had strongyle eggs in their feces, but in general fewer than at pretreatment.

     

Determining Treatment to Control Two Multidrug-Resistant Parasites on a Texas Horse Farm

A study was undertaken at the Texas A&M Horse Center to evaluate and compare the effectiveness of three anthelmintics—ivermectin, fenbendazole, and a combination of ivermectin and pyrantel pamoate—on fecal egg count reductions of cyathostomes and Parascaris equorum in 30 naturally infected foals. The foals were randomized into three treatment groups, with individuals being rerandomized after each 8-week observation period. The treatments of ivermectin and fenbendazole were given at the manufacturer's recommended doses, and the pyrantel treatment was given at two times the manufacturer's recommended dose. Fecal egg counts were performed at the time of treatment and at 2-week intervals after treatment for a total of 8 weeks. Each foal received a total of three treatments during the course of the study. Fecal egg counts were performed by a modified McMaster's test, with a sensitivity of 25 eggs per gram of feces, and by the modified Wisconsin double centrifugal flotation technique, with a sensitivity of 0.2 eggs per gram of feces. Fecal egg reduction percentages were calculated. Analysis of the results showed that ivermectin, either used alone or with pyrantel, was a more effective anthelmintic for cyathostome (small strongyle) control than fenbendazole. Fenbendazole and pyrantel showed a higher initial reduction in Parascaris egg counts when compared with the ivermectin-only-treated group, but this difference lessened over time. The use of the combination treatment showed the best results for controlling both parasites, indicating that a combination of anthelmintics may be necessary to control parasites on some equine farms.     

Evidence of Ivermectin Resistance by Parascaris equorum on a Texas Horse Farm

By collecting fecal samples every 2 weeks beginning at 2 months of age, 32 foals from a single Texas farm were monitored. The foals were administered ivermectin paste at the time of the first collection and again monthly. When foals had Parascaris egg counts higher 2 weeks after ivermectin treatment than at treatment, they were administered pyrantel pamoate at the manufacturer's recommended dose (6.6 mg/kg) or at twice the recommended dose (13.2 mg/ kg) when tapeworm eggs were also detected. An elevation or only minimal reduction (less than 75%) in Parascaris egg counts was seen 2 weeks after ivermectin treatment until the foals were 8 months of age, at which time there was an 85% reduction in fecal egg count after treatment. When pyrantel was administered at the manufacturer's recommended dose, a 42% to 84% reduction in egg counts occurred, but at 13.2 mg/kg there was a 98% to 100% reduction in fecal egg counts 2 weeks posttreatment. However, pyrantel failed to control strongylate egg counts even at the elevated dose, whereas ivermectin reduced strongylate fecal egg counts by greater than 99%, determined 2 weeks posttreatment. Pyrantel, but not ivermectin, lowered Parascaris egg counts. Ivermectin, but not pyrantel, lowered strongyle egg counts 2 weeks post administration. A single drug for all ages of horses approach to parasite control requires rethinking. Combinations of drugs or more careful evaluation of anthelmintics in foals may be necessary for continued parasite control.     

Field efficacy of ivermectin plus praziquantel oral paste against naturally acquired gastrointestinal nematodes and cestodes of horses in North America and Europe

The efficacy of an oral formulation of ivermectin plus praziquantel in the reduction of nematode and cestode egg counts in horses was assessed in 273 horses under field conditions at 15 sites in North America (n = 6) and Europe (n = 9). Horses were confirmed by fecal examination to have natural infections of strongyles (100%) and tapeworms (76%). Replicates of four horses were formed at each site, and in each replicate three animals received ivermectin (0.2 mg/kg body weight) plus praziquantel (1 mg/kg body weight) oral paste and one animal remained untreated or received vehicle paste. Fecal samples were collected for fecal nematode and cestode egg counting before and 7, 8, 9, 14, 15, and 16 days after treatment. Horses treated with ivermectin plus praziquantel oral paste had significantly (P <.01) lower posttreatment strongylid and cestode egg counts (reductions of 98% or more) than controls. Combined site analyses revealed that 95% or 96% of the horses positive for cestode eggs before treatment that were treated with ivermectin plus praziquantel were negative for cestode eggs at each posttreatment fecal examination. No adverse reactions attributable to ivermectin plus praziquantel oral paste treatments were observed. The results of the studies demonstrated that ivermectin plus praziquantel paste was highly effective in reducing egg shedding by gastrointestinal nematodes and cestodes, and no adverse reactions were observed in horses treated under field conditions.     

Identification of foals infected with Parascaris equorum apparently resistant to ivermectin

During September 2002, routine fecal examinations performed on 16 Thoroughbred foals residing on a farm outside Toronto, Ontario, Canada, revealed low to moderate numbers of Parascaris equorum eggs in feces from 9 of the 16. All foals were then treated with ivermectin at a dose of 220 to 280 microg/kg (100 to 127 microg/lb), p.o., and fecal egg counts were repeated 12 days later. Fecal P. equorum egg counts increased between the first and second fecal examination in 7 foals, were unchanged in 1, and decreased in 5. Fecal samples were collected 13 days after treatment from 21 additional foals that had been treated with ivermectin at the same dose, and P. equorum eggs were detected in 12 of the 21. For all 37 foals, high P. equorum egg counts (> or = 100 eggs/g of feces) 12 to 13 days after ivermectin treatment were significantly more likely in foals that had been regularly treated with ivermectin since birth and permanently resided on the farm, compared with foals that had been treated with other anthelmintics or had an unknown deworming history. Collectively, these data suggested that P. equorum in these foals was resistant to ivermectin administered at the recommended dose.     

Control of cyathostome infections in mares treated at parturition with ivermectin

Six mares were treated on the day of parturition with an intramuscular injection of 0.2 mg kg-1 ivermectin and placed in a pasture free of equine parasites as soon as possible after foaling. The mares and their foals were compared with a similar group of untreated mares and foals on an adjoining pasture. The experimental data was derived from mare and foal fecal egg counts, foal necropsies and pasture larval counts. Ivermectin administered to mares on the day of parturition, when combined with movement to parasite-free pastures, significantly lowered the cyathostome (small strongyle) egg production for 4 months. This reduced cyathostome exposure was reflected in lower worm-burdens in their foals for 5 months. The results indicate that ivermectin will effectively control equine strongyles when mares and their foals are moved to parasite-free pastures.     

Efficacy of avermectin B1 given orally against equine intestinal strongyles and Onchocera microfilaria

Three groups of horses and ponies (N = 13, 13 and 12) were treated with ivermectin paste (0.2 mg/kg p.o.), avermectin B1 solution (0.2 mg/kg p.o.), or fenbendazole suspension (10 mg/kg via nasogastric tube). The avermectin B1 was a 1% solution in a propylene glycolglycerol formal base. Faecal strongyle egg counts were performed before, and 14, 28, 42, 56 and 70 d, after treatment. Full-thickness skin biopsies from the neck, pectoral and umbilical regions were examined for Onchocera microfilaria before treatment, and again 14 and 70 d later. Ivermectin therapy produced a significant (P less than 0.01) decrease in mean strongyle egg counts 14, 28, 42 and 56 d after treatment. Avermectin B1 therapy resulted in significant (P less than 0.01) decreases in mean strongyle egg counts 14, 28 and 42 d after treatment. All horses given ivermectin or avermectin B1 had zero strongyle egg counts 14 and 28 d after treatment. Fenbendazole failed to significantly decrease strongyle egg counts. Both ivermectin and avermectin B1 resulted in zero microfilaria counts in all horses 14 d after treatment. On day 70 the percentage decrease in microfilaria counts were 100% and 99.6% respectively. Fenbendazole failed to significantly decrease microfilaria counts. The oral administration of this formulation of avermectin B1 appeared to be highly efficacious against intestinal strongyles and Onchocera microfilaria. The duration of anti-strongyle activity was, however, significantly (P less than 0.01) shorter than that of ivermectin paste.     

Prevalence of strongyles and efficacy of fenbendazole and ivermectin in working horses in El Sauce, Nicaragua

Horses, mules and donkeys are indispensable farming and working animals in many developing countries, and their health status is important to the farmers. Strongyle parasites are ubiquitous in grazing horses world-wide and are known to constitute a threat to equine health. This study determined the prevalence of strongyle infection, the efficacy of ivermectin and fenbendazole treatment, and strongyle re-infection rates of working horses during the dry months in Nicaragua. One hundred and five horses used by farmers for transport of people and goods were randomly allocated into three treatment groups, i.e., the IVM group treated with ivermectin, the FBZ group treated with fenbendazole and the control group treated with placebo. Determined by pre-treatment faecal egg counts (FECs), horses showed a high prevalence (94%) of strongyle parasites with high intensities of infection (mean FEC of 1117 eggs per gram (EPG) with an SD of 860 EPG, n=102). Body condition scores of all horses ranged from 1.5 to 3.5 with a mean of 2.4 (scales 1-5). Fourteen days after treatment faecal egg count reductions (FECRs) were 100% and 94% in the IVM and the FBZ groups, respectively. The egg reappearance period (ERP) defined as the time until the mean FEC reached 20% of the pre-treatment level, was estimated as 42 days for the FBZ group and 60 days for the IVM group. Individual faecal cultures were set up and the larval differentiation revealed a 36% prevalence of Strongylus vulgaris before treatment (n=45). In the FBZ group, 25% of the horses were S. vulgaris-positive 70 days post treatment compared to 11% in the IVM group. Our results indicate that strongyle infection intensities in Nicaragua are high and that S. vulgaris is endemic in the area. Furthermore, efficacies and ERPs of IVM and FBZ were within the expected range with no signs of anthelmintic resistance.     

Efficacy of Ivermectin Pour-on Against Nematodes Infecting Foals on Pasture: Coprological and Biochemical Analysis

The efficacy of topical ivermectin (IVM) on foals naturally infected by parasitic nematodes was evaluated. Two dosages of IVM were applied pour-on (F-Nor0.5; 0.5 mg/kg body weight [BW] and F-Nor1; 1 mg/kg BW) and results compared with the oral administration (F-Eq0.2; 0.2 mg/kg BW of IVM). The efficacy was measured by estimating the reduction in the fecal egg counts (fecal egg count reduction) and in the numbers of horses shedding parasite eggs (positive horse reduction). Several biochemical and enzymatic serum parameters were measured in the groups F-Eq0.2 and F-Nor1. Before the deworming of the horses, eggs of Parascaris equorum, Cyathostomum, Gyalocephalus spp, and Oxyuris equi were identified. In all the treated groups, the excretion of ascarid eggs ended 4 days after the treatment. The orally administered IVM suppressed the egg output of strongyles and pinworms 4 days after the treatment, whereas for the F-Nor1 group this occurred 8 days after the treatment. Eggs of strongyles were detected in the F-Nor0.5 group throughout the study. The levels of blood urea nitrogen, creatinine, total proteins, albumin, globulins, and lactate dehydrogenase (LDH) reduced significantly after the administration of IVM, but values not within the normal range were only achieved for LDH. A significant positive correlation between the fecal egg output of cyathostomins and the LDH was investigated. Clinically, no adverse reactions in the horses receiving the topical IVM were observed. It was concluded that the pour-on administration of 1 mg/kg BW IVM provides similar results to the oral administration, and offers a very useful tool to control infestation by the intestinal nematodes affecting wild grazing horses.     

Epidemiological approach to the control of horse strongyles

An investigation of the spring rise in strongyle egg output of grazing horses on two commercial horse farms in northern USA in 1981 and 1982 revealed two distinct spring and summer rises in faecal egg counts, with peaks in May and August/September. There was a marked rise in the concentration of infective larvae on pasture two to four weeks after the peaks in egg output, so that grazing horses were at serious risk from June onwards and pasture larval counts on one farm did not fall to low levels until June of the following year. The spring and summer rises in faecal egg counts appeared to be seasonal in nature, to be derived largely from worms developing from previously ingested larvae, rather than from newly ingested larvae, and to be unrelated to the date of foaling. An epidemiological approach to strongyle control based on prophylactic treatments in the spring successfully eliminated the spring rise in egg output but was inadequate to control the summer rise or subsequent escalation of pasture infectivity in September. It was, nevertheless, superior to a conventional treatment programme at eight week intervals, using the same drug, pyrantel pamoate. Prophylactic spring/summer treatments proved to be much more effective. Both pyrantel pamoate at four week intervals and ivermectin at eight week intervals kept faecal egg counts at low levels during spring and summer. As few as two ivermectin treatments (11 May, 6 July) resulted in a sixfold reduction in pasture larval counts on 9 November and 3 January for the treated group (8872, 8416 stage three larvae [L3]/kg) compared to the control group (52,824, 50,984 L3/kg).(ABSTRACT TRUNCATED AT 250 WORDS)